ArticleJFMS open reports
Successful response to cabergoline treatment in a non-diabetic cat with hypersomatotropism and pituitary macroadenoma.
Article in JFMS open reports. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Case summary: A 12-year-old male neutered domestic shorthair cat was referred with severe polyphagia, polydipsia, polyuria, weight gain and signs of neurologic disease, including blindness, head tilt, and ataxia. Magnetic resonance imaging (MRI) identified a suprasellar mass consistent with a pituitary macroadenoma. Hypersomatotropism (HST) was diagnosed based on phenotypic changes compatible with acromegaly and an abnormally high serum insulin-like growth factor 1 (IGF-1) concentration (1253 ng/ml). Medical treatment with cabergoline monotherapy (10 μg/kg PO q24h) was prescribed. Progressive improvement of clinical signs was observed, accompanied by a gradual decrease in serum IGF-1 concentrations. Based on clinical and hormonal response, the dosing interval was sequentially extended to q48h and subsequently to q72h. By week 16 of treatment, signs of neurologic disease had resolved and serum IGF-1 concentrations decreased to values within the reference interval (749 ng/ml), while visual deficits persisted. By week 30, signs of neurologic disease remained absent, serum IGF-1 concentration was maintained within the reference interval, and diabetes mellitus did not develop. Cabergoline was well tolerated, with mild gastrointestinal signs reported early in the course of treatment. Relevance and novel information: This report describes a non-diabetic cat with HST secondary to a pituitary macroadenoma achieving sustained clinical and biochemical control with cabergoline monotherapy. This case demonstrates that a dopamine agonist might be an effective medical option in selected non-diabetic cats with HST, even in the presence of a large pituitary mass and signs of neurologic disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.